X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (557) 557
Publication (30) 30
Book Review (15) 15
Newspaper Article (4) 4
Book Chapter (3) 3
Newsletter (2) 2
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alendronate (381) 381
humans (326) 326
index medicus (262) 262
female (246) 246
osteoporosis (229) 229
animals (226) 226
pharmacology & pharmacy (182) 182
bisphosphonates (178) 178
male (169) 169
alendronate - pharmacokinetics (135) 135
rats (126) 126
middle aged (105) 105
osteoporosis - drug therapy (96) 96
postmenopausal women (96) 96
bone density conservation agents - pharmacokinetics (95) 95
aged (94) 94
bone density conservation agents - administration & dosage (94) 94
endocrinology & metabolism (94) 94
alendronate - administration & dosage (93) 93
pharmacokinetics (89) 89
bone density - drug effects (88) 88
diphosphonates - pharmacokinetics (88) 88
bisphosphonate (83) 83
postmenopausal osteoporosis (83) 83
osteoporosis, postmenopausal - drug therapy (82) 82
bone density conservation agents - therapeutic use (80) 80
bone-mineral density (76) 76
alendronate - therapeutic use (73) 73
bone (71) 71
women (71) 71
bone density conservation agents - adverse effects (65) 65
bone and bones - metabolism (64) 64
diphosphonates - administration & dosage (64) 64
in-vitro (64) 64
mice (62) 62
drug therapy (60) 60
diphosphonates - therapeutic use (59) 59
research (58) 58
alendronate - pharmacology (57) 57
risedronate (57) 57
alendronate - chemistry (56) 56
bone and bones - drug effects (56) 56
fractures (56) 56
administration, oral (55) 55
bone density (55) 55
bone density conservation agents - pharmacology (54) 54
diphosphonates - adverse effects (54) 54
bones (52) 52
therapy (52) 52
adult (51) 51
orthopedics (51) 51
zoledronic acid (51) 51
biological availability (49) 49
dose-response relationship, drug (47) 47
rats, sprague-dawley (46) 46
diphosphonates - pharmacology (45) 45
alendronate - adverse effects (43) 43
analysis (42) 42
drugs (40) 40
etidronic acid - analogs & derivatives (39) 39
health aspects (38) 38
vertebral fractures (38) 38
bone resorption (37) 37
drug administration schedule (37) 37
resorption (37) 37
bone mineral density (36) 36
bone remodeling - drug effects (36) 36
tissue distribution (36) 36
double-blind method (35) 35
drug delivery systems (35) 35
medicine, general & internal (35) 35
nanoparticles (35) 35
pamidronate (35) 35
time factors (35) 35
absorption (34) 34
bioavailability (34) 34
chemistry, multidisciplinary (34) 34
rats, wistar (34) 34
care and treatment (33) 33
treatment outcome (33) 33
turnover (33) 33
dosage and administration (32) 32
aged, 80 and over (31) 31
alendronic acid (31) 31
fractures, bone - prevention & control (31) 31
phosphonates (31) 31
medicine, research & experimental (30) 30
rheumatology (30) 30
risk (30) 30
risedronate sodium (29) 29
density (28) 28
diphosphonates (28) 28
medicine & public health (28) 28
efficacy (27) 27
hydroxyapatite (27) 27
cell line, tumor (26) 26
double-blind (26) 26
pharmacology (26) 26
therapeutic equivalency (26) 26
area under curve (25) 25
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (547) 547
Spanish (5) 5
Japanese (4) 4
French (2) 2
German (2) 2
Norwegian (2) 2
Danish (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 05/2013, Volume 75, Issue 5, pp. 1240 - 1254
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 10/2017, Volume 264, pp. 76 - 88
Bone is the most common organ affected by metastatic breast cancer. Targeting cancers within the bone remains a great challenge due to the inefficient delivery... 
Coordination polymer nanoparticles | Bone metastasis | Bone targeting | Alendronate | Cisplatin | CALCIUM-PHOSPHATE NANOPARTICLES | SYSTEM | EFFICACY | BIODISTRIBUTION | MODEL | HYDROXYAPATITE | CHEMISTRY, MULTIDISCIPLINARY | DELIVERY | POLY(ETHYLENE GLYCOL) | PHARMACOLOGY & PHARMACY | LIPOSOMES | Prodrugs - administration & dosage | Zinc - administration & dosage | Cisplatin - pharmacokinetics | Nanoparticles - chemistry | Humans | Bone Neoplasms - secondary | Drug Carriers - administration & dosage | Male | Polyethylene Glycols - chemistry | Prodrugs - chemistry | Antineoplastic Agents - administration & dosage | Zinc - chemistry | Metal-Organic Frameworks - chemistry | Drug Carriers - chemistry | Alendronate - chemistry | Bone Neoplasms - metabolism | Breast Neoplasms - metabolism | Cisplatin - administration & dosage | Cisplatin - chemistry | Zinc - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Bone Neoplasms - drug therapy | Alendronate - pharmacokinetics | Cell Survival - drug effects | Polyethylene Glycols - pharmacokinetics | Metal-Organic Frameworks - administration & dosage | Antineoplastic Agents - chemistry | Breast Neoplasms - drug therapy | Metal-Organic Frameworks - pharmacokinetics | Rats, Sprague-Dawley | Polyethylene Glycols - administration & dosage | Xenograft Model Antitumor Assays | Animals | Prodrugs - pharmacokinetics | Breast Neoplasms - pathology | Mice, Nude | Cell Line, Tumor | Drug Liberation | Drug Carriers - pharmacokinetics | Mice, Inbred BALB C | Nanoparticles - administration & dosage | Alendronate - administration & dosage | Nanoparticles | Care and treatment | Chemotherapy | Polyethylene glycol | Digital signal processors | Aluminum compounds | Breast cancer | Metastasis | Polymer industry | Polyols | Cancer | Zinc compounds | Index Medicus
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 6, pp. 940 - 952
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 12/2017, Volume 268, pp. 92 - 101
Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders and clonal hematopoietic stem cell disorders characterized by abnormal blood... 
Bone marrow | Decitabine | Arsenic trioxide | Delivery | Nanoparticle | Myelodysplastic syndrome | APOPTOSIS | DNA METHYLATION | DRUG-DELIVERY | 5-AZACYTIDINE | COMBINATION | CANCER | CHEMISTRY, MULTIDISCIPLINARY | CHEMOTHERAPY | RETINOIC ACID | PHARMACOLOGY & PHARMACY | POLYMER HYBRID NANOPARTICLES | ACUTE PROMYELOCYTIC LEUKEMIA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nanoparticles - chemistry | Apoptosis - drug effects | Oxides - chemistry | Azacitidine - chemistry | Phosphatidylethanolamines - therapeutic use | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Polyethylene Glycols - therapeutic use | Alendronate - chemistry | Alendronate - therapeutic use | Tissue Distribution | Arsenicals - therapeutic use | Nanoparticles - therapeutic use | Bone and Bones - metabolism | Phosphatidylethanolamines - pharmacokinetics | Bone Marrow Cells - drug effects | Antineoplastic Agents - pharmacokinetics | Arsenicals - pharmacokinetics | Alendronate - pharmacokinetics | Myelodysplastic Syndromes - drug therapy | Oxides - administration & dosage | Azacitidine - administration & dosage | Oxides - therapeutic use | Cell Survival - drug effects | Arsenic Trioxide | Azacitidine - pharmacokinetics | Myelodysplastic Syndromes - metabolism | Cells, Cultured | Polyethylene Glycols - pharmacokinetics | Azacitidine - analogs & derivatives | Mice, Transgenic | Phosphatidylethanolamines - administration & dosage | Antineoplastic Agents - chemistry | Polyethylene Glycols - administration & dosage | Oxides - pharmacokinetics | Arsenicals - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Arsenicals - chemistry | Nanoparticles - administration & dosage | Phosphatidylethanolamines - chemistry | Alendronate - administration & dosage | Azacitidine - therapeutic use | Medical research | Medical colleges | Medical examination | Arsenic | Analysis | Medicine, Experimental | Hematopoietic stem cells | Blood | Index Medicus | delivery | nanoparticle | decitabine | arsenic trioxide | bone marrow
Journal Article
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 2011, Volume 416, Issue 1, pp. 305 - 313
It has been proposed that localized and controlled delivery of alendronate and tetracycline to periodontal pocket fluids via guided tissue regeneration (GTR)... 
Layered double hydroxide clay | Alendronate | Controlled release | Poly(lactic-co-glycolic acid) | Guided tissue regeneration | Tetracycline | IN-VITRO RELEASE | PERIODONTAL-DISEASES | ANIONIC CLAYS | ATTACHMENT | MEMBRANES | PROLIFERATION | BISPHOSPHONATES | DELIVERY SYSTEM | TETRACYCLINES | PHARMACOLOGY & PHARMACY | DIFFERENTIATION | Nanocomposites - chemistry | Biocompatible Materials - chemistry | Tetracycline - chemistry | Alkaline Phosphatase - metabolism | Drug Carriers - chemistry | Alendronate - chemistry | Biocompatible Materials - chemical synthesis | Lactic Acid - pharmacokinetics | Aluminum Silicates - chemistry | Guided Tissue Regeneration - methods | Surface Properties | Alendronate - pharmacokinetics | Cell Survival - drug effects | Hydroxides - chemistry | Lactic Acid - chemistry | Osteoblasts - drug effects | Osteogenesis - drug effects | Cells, Cultured | Rats | Biocompatible Materials - pharmacology | Rats, Sprague-Dawley | Particle Size | Animals | Aluminum Silicates - pharmacokinetics | Polyglycolic Acid - pharmacokinetics | Polyglycolic Acid - chemistry | Drug Carriers - pharmacokinetics | Biocompatible Materials - pharmacokinetics | Tetracycline - pharmacokinetics | Osteoblasts - metabolism | Tetracycline - administration & dosage | Drug Combinations | Alendronate - administration & dosage | Nanocomposites - administration & dosage | Hydroxides | Green technology | Universities and colleges
Journal Article